Sökning: onr:"swepub:oai:gup.ub.gu.se/280755" >
Sofosbuvir/velpatas...
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
2018-11-30
-
Informa UK Limited,2019
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/280755
-
https://gup.ub.gu.se/publication/280755URI
-
https://doi.org/10.1080/23744235.2018.1535186DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:140696566URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy. An effective pangenotypic therapy may potentially eliminate the need for genotyping. In this study, we evaluated the efficacy and safety of sofosbuvir/velpatasvir for 12 weeks in patients from Russia and Sweden. Methods: In an open-label, single-arm phase-3 study, patients could have HCV genotype 1-6 infection and were treatment-naive or interferon treatment-experienced. All patients received sofosbuvir/velpatasvir, once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12). Results: Of 122 patients screened, 119 were enrolled and treated. Overall, half (50%) were male, 18% had cirrhosis, and 24% had failed prior interferon-based therapy. In total, 66% of patients were infected with HCV genotype 1 (59% 1b and 7% 1a), 6% with genotype 2, and 29% with genotype 3. The overall SVR12 rate was 99% (118/119, 95% confidence interval 95-100%). One treatment-experienced patient infected with HCV genotype 3 experienced virologic relapse after completing treatment. The most common adverse events were headache (16%) and fatigue (7%). Serious adverse events were observed in four patients, but none were related to treatment. No patients discontinued treatment due to adverse events. Conclusion: Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3. Sofosbuvir/velpatasvir was safe and well-tolerated.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Chulanov, V.
(författare)
-
Abdurakhmanov, D.
(författare)
-
Burnevich, E.
(författare)
-
Nurmukhametova, E.
(författare)
-
Kozhevnikova, G.
(författare)
-
Gankina, N.
(författare)
-
Zhuravel, S.
(författare)
-
Romanova, S.
(författare)
-
Hyland, R. H.
(författare)
-
Lu, S.
(författare)
-
Svarovskaia, E. S.
(författare)
-
McNally, J.
(författare)
-
Brainard, D. M.
(författare)
-
Ivashkin, V.
(författare)
-
Morozov, V.
(författare)
-
Bakulin, I.
(författare)
-
Lagging, Martin,1965Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine(Swepub:gu)xlagma
(författare)
-
Zhdanov, K.
(författare)
-
Weiland, O.Karolinska Institutet
(författare)
-
Göteborgs universitetInstitutionen för biomedicin, avdelningen för infektionssjukdomar
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Infectious Diseases: Informa UK Limited51:2, s. 131-1392374-42352374-4243
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Isakov, V.
-
Chulanov, V.
-
Abdurakhmanov, D ...
-
Burnevich, E.
-
Nurmukhametova, ...
-
Kozhevnikova, G.
-
visa fler...
-
Gankina, N.
-
Zhuravel, S.
-
Romanova, S.
-
Hyland, R. H.
-
Lu, S.
-
Svarovskaia, E. ...
-
McNally, J.
-
Brainard, D. M.
-
Ivashkin, V.
-
Morozov, V.
-
Bakulin, I.
-
Lagging, Martin, ...
-
Zhdanov, K.
-
Weiland, O.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Infectious Disea ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet